Cartesian Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Cartesian Therapeutics, Inc. (RNAC) reported Cash and Cash Equivalents, Period Increase (Decrease) of $11.97 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-15
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$1.53M.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$10.48M.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $55.99M, a 14.64% decline year-over-year.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$32.02M.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $11.97M, a 54.53% decline from fiscal 2016.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $26.32M, a 67.16% increase from fiscal 2015.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $15.74M, a 84.48% increase from fiscal 2014.
- Cartesian Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $8.54M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$12.01M derived: sum of 2 quarters · filed 2018-03-15 | $43.98M derived: sum of 3 quarters · filed 2018-03-15 | $11.97M 10-K · filed 2018-03-15 |
| 2017-09-30 | -$10.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $45.51M derived: sum of 2 quarters · filed 2017-11-07 | $13.49M 10-Q · filed 2017-11-07 | $12.66M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | $55.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $23.97M 10-Q · filed 2017-08-11 | $23.14M derived: sum of 3 quarters · filed 2018-03-15 | -$18.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | -$32.02M 10-Q · filed 2017-05-11 | -$32.85M derived: sum of 2 quarters · filed 2018-03-15 | -$56.01M derived: sum of 3 quarters · filed 2018-03-15 | $9.59M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | -$832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$23.99M derived: sum of 2 quarters · filed 2018-03-15 | $41.60M derived: sum of 3 quarters · filed 2018-03-15 | $26.32M 10-K · filed 2018-03-15 |
| 2016-09-30 | -$23.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $42.44M derived: sum of 2 quarters · filed 2017-11-07 | $27.15M 10-Q · filed 2017-11-07 | $21.97M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $65.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $50.31M 10-Q · filed 2017-08-11 | $45.13M derived: sum of 3 quarters · filed 2018-03-15 | $69.49M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | -$15.29M 10-Q · filed 2017-05-11 | -$20.46M derived: sum of 2 quarters · filed 2018-03-15 | $3.90M derived: sum of 3 quarters · filed 2018-03-15 | |
| 2015-12-31 | -$5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $19.18M derived: sum of 2 quarters · filed 2018-03-15 | $15.74M 10-K · filed 2018-03-15 | |
| 2015-09-30 | $24.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $20.92M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | -$3.44M 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | $8.54M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |